Analysis / Analysis
Analysis

PABS: An Unresolved Bargain—and a Question of Priorities

CGHA assesses the unresolved PABS negotiations and the opportunity costs of a pandemic agenda that must be weighed against established health burdens.
CGHANovember 2026
PABS: An Unresolved Bargain—and a Question of Priorities

Despite optimistic statements about progress and renewed solidarity, negotiations over the World Health Organization’s Pathogen Access and Benefit-Sharing system, known as PABS, have left central disagreements unresolved. CGHA’s assessment is that a substantive agreement remains some distance away. But the larger question is whether the time, money and political attention devoted to this process are proportionate to the risks it seeks to address.

PABS is intended to connect access to pathogens and associated information with benefits for participating countries, including access to medical products. Countries supplying material and data want credible returns. Governments and companies expected to provide those benefits resist obligations whose costs and scope remain uncertain.

The ambition for a comprehensive, openly accessible digital pathogen-sharing hub has encountered substantial resistance. A hybrid or restricted arrangement appears increasingly likely, with governments retaining greater control over information they supply. Countries recognize that pathogen data have commercial as well as scientific value. They are reluctant to surrender that value against uncertain promises.

Benefit sharing remains equally contentious. Charges for accessing data, financial transfers supporting surveillance and diagnostics, and preferential access to resulting products all face objections. Pharmaceutical companies want inexpensive, predictable access for research. Funding governments resist additional commitments. Product discounts are difficult to negotiate before production costs and circumstances of demand are known.

Countries are consequently being asked to support expensive systems without sufficient clarity about what they will receive. Potential concessions for low-income countries offer limited reassurance to middle-income countries expected to make substantial investments themselves. Uncertainty about which health emergencies would trigger obligations further complicates the bargain.

These are legitimate technical problems. Resolving them, however, would not establish that the wider expenditure is justified. Useful arrangements for sharing pathogens and responding to outbreaks should be developed. Their value must still be assessed against the likelihood and scale of the harm they could prevent—and against what the same resources could achieve elsewhere.

Severe outbreaks are possible, but the probability of another exceptionally costly pandemic within any given year is low and uncertain. The enormous disruption associated with COVID-19 should not become an unquestioned baseline for recurring expenditure. Assessments must also distinguish harm caused by infection from harm caused by policy responses. Otherwise, governments risk financing an expanding preparedness apparatus against inflated expectations of its benefits.

The opportunity costs are substantial. Money, skilled personnel and ministerial attention devoted to pandemic negotiations cannot simultaneously address tuberculosis, malaria, cardiovascular disease, inadequate basic care and other established burdens. These cause measurable harm today. Their claims on scarce resources should carry considerable weight alongside projections of future emergencies.

The next WHO director-general must confront this imbalance. A change of leadership should bring a reassessment of priorities, rather than another effort to secure agreement within an agenda already shaped by powerful institutional, commercial and philanthropic interests. Those interests may benefit from expanding surveillance, procurement and preparedness programs; their enthusiasm does not establish the public-health case.

For CGHA, the priority is proportionate preparedness within a broader commitment to better health. PABS needs a credible bargain. WHO needs leadership willing to judge that bargain—and the resources devoted to it—against the diseases and deficiencies already shortening millions of lives.